#United States #Class Action #San Francisco #Hagens Berman #Regeneron

Investors Alert: Regeneron Pharmaceuticals Class Action

On August 26, 2026, Hagens Berman Sobol Shapiro LLP, a national law firm recognized for its work in securities class action litigation, announced a notice to investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This alert comes as a response to a recently filed class action lawsuit that highlights significant concerns regarding the company's Phase 3 clinical trial outcomes related to melanoma treatment.

Background of the Case

The class action lawsuit was initiated after Regeneron disclosed disappointing results from a critical clinical trial involving a drug intended to treat melanoma. Following the revelation that the trial failed to meet its primary endpoint—progression-free survival (PFS)—the company's stock experienced a severe drop, erasing approximately $11 billion from its market cap. Investors who purchased or acquired Regeneron shares between August 1, 2025, and May 15, 2026, are encouraged to join the lawsuit as lead plaintiffs by the set deadline of September 14, 2026.

The Clinical Trial Failures

The lawsuit focuses on the Phase 3 trial of Fianlimab, which was combined with Libtayo as a proposed first-line treatment for metastasized or locally advanced melanoma. Regeneron's management had previously characterized this trial as a potential 'blockbuster,' inferring a high level of confidence in its success. However, the disappointing results have led to allegations of false and misleading statements from the company regarding the trial's statistical significance and results.

According to the complaint, Regeneron's management failed to inform investors about critical flaws in the statistical assumptions of the trial, leading to a significant misrepresentation regarding the expected efficacy of the treatment. As the events leading to the primary analysis slowed down, Regeneron maintained a misleading sense of optimism that the trial would achieve its set goals, which has since been shown to be unfounded.

Timeline of Events

1. April 29, 2026: Regeneron disclosed a protocol change in the trial, indicating that the primary analysis would include all patients enrolled with a minimum of six months' follow-up. This raised concerns among analysts about the trial's viability.
2. May 12, 2026: The company acknowledged the alteration was made due to unexpectedly slow event rates—a warning sign that significantly contradicted previous statements of confidence.
3. May 15, 2026: The final and most shocking announcement came when Regeneron reported that the trial did not achieve statistical significance in improving progression-free survival.

Legal Implications

Reed Kathrein, the Hagens Berman partner leading the investigation, emphasized the need to ascertain whether Regeneron altered its trial protocols without adequately informing investors, thereby misrepresenting the treatment's potential significantly. The firm is calling on investors who experienced substantial losses to share their experiences and join the lawsuit.

Whistleblower Opportunities

Additionally, the firm encourages individuals with non-public information about Regeneron to consider becoming whistleblowers. There are potential rewards for whistleblowers through the SEC Whistleblower program, which can offer payments up to 30% of any successful recovery made by the SEC.

Conclusion

In conclusion, this unfolding scenario highlights the consequences entities face when they fail to provide accurate information to their investors. As the case develops, shareholders are advised to stay informed and consider their options carefully in light of these significant legal proceedings. For more information on how to engage in the class action lawsuit or remain updated on the developments, interested parties can visit the Hagens Berman website or contact their offices directly.

For any inquiries or assistance regarding this matter, reach out to Hagens Berman at 844-916-0895 or via their website.

This alert serves as a crucial reminder for all investors regarding the imperative necessity of transparency and integrity within the pharmaceutical sector, particularly in light of potentially life-changing therapies.

• ---

About Hagens Berman: Hagens Berman is a globally recognized law firm dedicated to protecting the rights of investors and holding corporations accountable for negligence. The firm emphasizes creating impactful change through legal advocacy and has successfully recovered billions for individuals impacted by corporate wrongdoing.